The UK and US have established a key bilateral deal that will ensure zero duties on UK drug products entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost funding on medicines through the public health system. This pledge secures that tariffs on these vital exports will stay at zero for a duration of three years.
This agreement is in response to recent threats to significantly raise import taxes on branded pharmaceutical imports, with figures discussed as high as 100%.
"This arrangement with the UK reinforces the international landscape for innovative medicines and brings long-overdue balance to American-British medicine commerce," an announcement said.
Trade Significance
Drugs constitute one of the Britain's most significant export categories to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Export figures show that in the year leading up to the third quarter, the UK sold pharmaceutical products worth £11.1bn to the US. This figure made up a significant portion of all goods exports in that timeframe.
"This guarantee secures employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Specific UK Commitments
The agreement entails several specific commitments from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The sum drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded 20%.
Recent Tensions
The deal follows a protracted row between the sector and the UK government over spending levels and approval rates.
This friction were intensified by arguments that American patients were paying several times more for the identical medicines than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or scrapped, while substantial funding commitments have been pledged toward projects in the United States.
One official stated that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a share of its resources over the previous ten-year period.
